Thyroid Cancer pp 297-304 | Cite as

Thyroglobulin and Thyroglobulin Antibodies

Measurement and Interferences
  • D. Robert Dufour
Chapter

Abstract

Thyroglobulin, an approximately 670-kDa glycopeptide, is the major protein product of thyroid follicular cells; its rate of synthesis is increased by thyrotropin (TSH). After synthesis, it is modified by the attachment of iodine to selected tyrosine residues, which undergo rearrangement to form iodothyronines, particularly thyroxine (T4) and, to a lesser extent, thysonine (T3). Other modifications of thyroglobulin also occur, including glycation and sulfation (1). The degree of TSH stimulation affects the extent of branching of carbohydrate side chains (2). There is variable processing of thyroglobulin, creating a family of proteins with different molecular structures around a common core peptide backbone. Interestingly, there is less variability in thyroglobulin structure in thyroid cancer than in other thyroid diseases (3). Reduced iodine content in thyroglobulin exists in patients with thyroid malignancy (4), which can lead to different recognition by monoclonal antibodies (5). This structural heterogeneity creates a challenge for thyroglobulin immunoassays, and results often differ significantly when using different thyroglobulin methods (6).

Keywords

Thyroid Cancer Differentiate Thyroid Cancer Differentiate Thyroid Carcinoma Serum Thyroglobulin Thyroid Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    van de Graaf S, Ris-Stalpers C, Pauws E, et al. Up to date with human thyroglobulin. J Endocrinol 2001; 170:307–321.PubMedCrossRefGoogle Scholar
  2. 2.
    Di Jeso B, Liguoro D, Ferranti P, et al. Modulation of the carbohydrate moiety of thyroglobulin by thyrotropin and calcium in Fisher rat thyroid line-5 cells. J Biol Chem 1992; 267:1938–1944.PubMedGoogle Scholar
  3. 3.
    Druetta L, Croizet K, Bornet H, Rousset B. Analyses of the molecular forms of serum thyroglobulin from patients with Graves’ disease, subacute thyroiditis or differentiated thyroid cancer by velocity sedimentation on sucrose gradient and Western blot. Eur J Endocrinol 1998; 139:498–507.PubMedCrossRefGoogle Scholar
  4. 4.
    Schneider A, Ikekubo K, Kuma K. Iodine content of serum thyroglobulin in normal individuals and patients. J Clin Endocrinol Metab 1983; 57:1251–1256.PubMedCrossRefGoogle Scholar
  5. 5.
    Kohno Y, Tarutani O, Sakata S, Nakajima H. Monoclonal antibodies to thyroglobulin elucidate differences in protein. J Clin Endocrinol Metab 1985; 61:343–350.PubMedGoogle Scholar
  6. 6.
    Spencer CA, Wang C. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 1995; 24:841–863.PubMedGoogle Scholar
  7. 7.
    Mazzaferri E, Robbins R, Spencer C, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433–1441.PubMedCrossRefGoogle Scholar
  8. 8.
    Feldt-Rasmussen U, Profilis C, Colinet E, et al. Human thyroglobulin reference material (CRM 457). 2nd Part Physicochemical characterization and certification. Ann Biol Clin 1996; 54:343–348.Google Scholar
  9. 9.
    Demers L, Spencer C. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13:3–126.PubMedCrossRefGoogle Scholar
  10. 10.
    Whitley RJ, Ain KB. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin Lab Med 2004; 24:29–47.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferrari L, Biancolini D, Seregni E, et al. Critical aspects of immunoradiometric thyroglobulin assays. Tumori 2003; 89:537–539.PubMedGoogle Scholar
  12. 12.
    Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996; 42:164–173.PubMedGoogle Scholar
  13. 13.
    Spencer CA. New insights for using serum thyroglobulin (Tg) measurement for managing patients with differentiated thyroid carcinomas. Thyroid Int 2003:3–14.Google Scholar
  14. 14.
    Kricka L. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45:942–956.PubMedGoogle Scholar
  15. 15.
    Levinson S, Miller J. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta 2002; 325:1–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Ward G, McKinnon L, Badrick T, Hickman P. Heterophilic antibodies remain a problem for the immunoassay laboratory. Am J Clin Pathol 1997; 108:417–421.PubMedGoogle Scholar
  17. 17.
    Weber T, Kapyaho K, Tanner P. Endogenous interference in immunoassays in clinical chemistry. A review. Scand J Clin Lab Invest Suppl 1990; 201:77–82.PubMedGoogle Scholar
  18. 18.
    Preissner C, O’Kane D, Singh R, et al. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003; 88:3069–3074.PubMedCrossRefGoogle Scholar
  19. 19.
    Marks V. False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. Clin Chem 2002; 48:2008–2016.PubMedGoogle Scholar
  20. 20.
    Marks V. False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. Clin Chem 2002; 48:2008–2016.PubMedGoogle Scholar
  21. 21.
    Fugazzola L, Mihalich A, Persani L, et al. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission. J Clin Endocrinol Metab 2002; 87:3201–3208.PubMedCrossRefGoogle Scholar
  22. 22.
    Wunderlich G, Zophel K, Crook L, et al. A high-sensitivity enzymelinked immunosorbent assay for serum thyroglobulin. Thyroid 2001; 11:819–824.PubMedCrossRefGoogle Scholar
  23. 23.
    Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83:1121–1127.PubMedCrossRefGoogle Scholar
  24. 24.
    Hjiyiannakis P, Mundy J, Harmer C. Thyroglobulin antibodies in differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 1999; 11:240–244.Google Scholar
  25. 25.
    Chiovato L, Latrofa F, Braverman L, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139:346–351.PubMedGoogle Scholar
  26. 26.
    Chung J, Park Y, Kim T, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002; 57:215–221.CrossRefGoogle Scholar
  27. 27.
    Bourrel F, Hoff M, Regis H, et al. Immunoradiometric assay of thyroglobulin in patients with differentiated thyroid carcinomas: need for thyroglobulin recovery tests. Clin Chem Lab Med 1998; 36:725–730.PubMedCrossRefGoogle Scholar
  28. 28.
    Erali M, Bigelow R, Miekle A. ELISA for thyroglobulin in serum: recovery studies to evaluate autoantibody interference and reliability of thyroglobulin value. Clin Chem 1996; 42:766–770.PubMedGoogle Scholar
  29. 29.
    Mariotti S, Barbesino G, Caturegli P, et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? J Clin Endocrinol Metab 1995; 80:468–472.PubMedCrossRefGoogle Scholar
  30. 30.
    Massart C, Maugendre D. Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves’ disease. Clin Chem 2002; 48:102–107.PubMedGoogle Scholar
  31. 31.
    Cubero J, Rodriguez-Espinosa J, Gelpi C, Estorch M, Corcoy R. Thyroglobulin autoantibody levels below the cut-off for positivity can interfere with thyroglobulin measurement. Thyroid 2003; 13:659–661.PubMedCrossRefGoogle Scholar
  32. 32.
    Gilmour J, Brownlee Y, Foster P, et al. The quantitative measurement of autoantibodies to thyroglobulin and thyroid peroxidase by automated microparticle based immunoassays in Hashimoto’s disease, Graves’ disease and a follow-up study on postpartum thyroid disease. Clin Lab 2000; 46:57–61PubMedGoogle Scholar
  33. 33.
    Lindberg B, Svensson J, Ericsson U, et al. Comparison of some different methods for analysis of thyroid autoantibodies: importance of thyroglobulin autoantibodies. Thyroid 2001; 11:265–269.PubMedCrossRefGoogle Scholar
  34. 34.
    Westbury C, Vini L, Fisher C, Harmer C. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid 2000; 10:171–176.PubMedGoogle Scholar
  35. 35.
    Sager P, Cooper D, Daniels G, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996; 256:2165–2172.Google Scholar
  36. 36.
    Tamizu A, Okumura Y, Sato S, et al. The usefulness of serum thyroglobulin levels and Tl-201 scintigraphy in differentiating between benign and malignant thyroid follicular lesions. Ann Nucl Med 2002; 16:95–101.PubMedCrossRefGoogle Scholar
  37. 37.
    Hocevar M, Auersperg M. Role of serum thyroglobulin in the preoperative evaluation of follicular thyroid tumours. Eur J Surg Oncol 1998; 24:553–557.PubMedCrossRefGoogle Scholar
  38. 38.
    Sharma A, Sarda A, Chattopadhyay T, Kapur M. The role of estimation of the ratio of preoperative serum thyroglobulin to the thyroid mass in predicting the behaviour of well differentiated thyroid cancers. J Postgrad Med 1996; 42:39–42.PubMedGoogle Scholar
  39. 39.
    Hrafnkelsson J, Tulinius H, Kjeld M, et al. Serum thyroglobulin as a risk factor for thyroid carcinoma. Acta Oncol 2000; 39:973–977.PubMedCrossRefGoogle Scholar
  40. 40.
    Hocevar M, Auersperg M, Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol 1997; 23:208–210.PubMedCrossRefGoogle Scholar
  41. 41.
    Lima N, Cavaliere H, Tomimori E, et al. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest 2002; 25:110–115.PubMedGoogle Scholar
  42. 42.
    Lin J, Huang M, Hsu B, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 2002; 80:45–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Ronga G, Filesi M, Ventroni G, et al. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999; 26:1448–1452.PubMedCrossRefGoogle Scholar
  44. 43a.
    Kim TY, Kim WB, Kim ES, et al. Serum Thyroglobulin levels at the time of 131-I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90:1440–1445.PubMedCrossRefGoogle Scholar
  45. 44.
    Van Wyngaarden K, McDougall I. Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue? Thyroid 1997; 7:343–346.PubMedGoogle Scholar
  46. 45.
    Grunwald F, Menzel C, Fimmers R, et al. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med 1996; 37:1962–1964.PubMedGoogle Scholar
  47. 46.
    Baudin E, Do Cao C, Cailleux A, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of followup after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003; 88:1107–1111.PubMedCrossRefGoogle Scholar
  48. 46a.
    David A, Blotta A, Rossi R, et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005; 15:267–273.PubMedCrossRefGoogle Scholar
  49. 47.
    Pacini F, Molinaro E, Castagna M, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:3668–3673.PubMedCrossRefGoogle Scholar
  50. 48.
    Pellegriti G, Scollo C, Regalbuto C, et al. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endocrinol (Oxf) 2003; 58:556–561.CrossRefGoogle Scholar
  51. 49.
    Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine wholebody scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87:1499–1501.PubMedCrossRefGoogle Scholar
  52. 50.
    Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to measurements to manage thyroid cancer without diagnostic 131-I scanning. J Clin Endocrinol Metab 2002; 87:1486–1489.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • D. Robert Dufour
    • 1
    • 2
    • 3
  1. 1.Pathology and Laboratory MedicineVeterans Affairs Medical CenterWashington, DC
  2. 2.George Washington University Medical CenterWashington, DC
  3. 3.Uniformed Services University of the Health SciencesBethesda

Personalised recommendations